Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?

Lancet Haematol. 2023 Dec;10(12):e942-e943. doi: 10.1016/S2352-3026(23)00311-3. Epub 2023 Oct 31.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Burkitt Lymphoma* / drug therapy
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Etoposide
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Prednisone / therapeutic use
  • Rituximab* / therapeutic use
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Cyclophosphamide
  • Doxorubicin
  • Prednisone
  • Rituximab
  • Vincristine

Supplementary concepts

  • EPOCH protocol